What's happened
AstraZeneca has announced that Wainua, its gene-silencer drug for transthyretin-mediated amyloid cardiomyopathy, did not meet its primary endpoint in a phase 3 trial. The news triggers a sharp stock drop and prompts investors to rethink the company’s long-term growth targets and the strength of its pipeline.
What's behind the headline?
Deep dive
- The market reaction exceeds the modest 2-4% hit to NPV estimates, signaling investor concern about pipeline credibility.
- Analysts had expected Wainua to contribute meaningfully to long-term sales, so the miss raises questions about management's confidence and forecasting discipline.
- The miss may compress upside for the company’s overall growth plan, forcing a reassessment of risk around other programmes in oncology and rare diseases.
- This event could hasten a shift in investor focus toward near-term cash generation and cost controls, while management defends the broader pipeline by highlighting other assets in development.
How we got here
Wainua, developed with Ionis, had been billed as a potential multiplier for AstraZeneca’s cardiovascular portfolio. The phase 3 CARDIO-TTRansform trial tested Wainua on top of standard care. The failure comes amid broader concerns about the durability of AstraZeneca’s late-stage successes and the sustainability of its growth target for 2030.
Our analysis
- The Independent: reports on AstraZeneca’s Wainua failure and its impact on the FTSE 100; quotes from market analysts and executives. - CNBC: coverage of stock drop and analyst commentary; discussion of Wainua’s potential value impact. - Bloomberg: notes that the failure blindsided investors and challenges long-held confidence in AstraZeneca’s pipeline.
Go deeper
- Will AstraZeneca realign its 2030 target in light of the Wainua miss?
- Which other assets in the pipeline are most at risk or most likely to offset the setback?
More on these topics
-
AstraZeneca - Pharmaceutical company
AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its global headquarters in Cambridge, England. Its R&D is concentrated in Cambridge, England, Mölndal in Sweden and North America.
-
United Kingdom - Country in Europe
The United Kingdom of Great Britain and Northern Ireland, commonly known as the United Kingdom or Britain, is a sovereign country located off the northwestern coast of the European mainland.
-
United States - Country in North America
The United States of America, commonly known as the United States or America, is a country mostly located in central North America, between Canada and Mexico.
-
Ionis Pharmaceuticals Inc - Biotechnology company
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics.
-
France - Country in Europe
France, officially the French Republic, is a country consisting of metropolitan France in Western Europe and several overseas regions and territories.
-
CNBC - Television channel
CNBC is an American pay television business news channel that is owned by NBCUniversal Worldwide News Group, a division of NBCUniversal, with both being ultimately owned by Comcast.
-
Germany - Country in Europe
Germany, officially the Federal Republic of Germany, is a country in Central and Western Europe. Covering an area of 357,022 square kilometres, it lies between the Baltic and North seas to the north, and the Alps to the south.
-
Europe - Region in Europe
Central Europe is the region comprising the central part of Europe. Central Europe occupies continuous territories that are otherwise sometimes considered parts of Western Europe, Southern Europe and Eastern Europe.
-
Cancer Research UK - Corporation
Cancer Research UK is a cancer research and awareness charity in the United Kingdom and Isle of Man, formed on 4 February 2002 by the merger of The Cancer Research Campaign and the Imperial Cancer Research Fund.
-
European Union
The European Union is a political and economic union of 27 member states that are located primarily in Europe. Its members have a combined area of 4,233,255.3 km² and an estimated total population of about 447 million.